Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cinrebafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cinrebafusp alfa overview
PRS-343 is under development for the treatment of HER2 low expressing and HER2 positive advanced or metastatic solid tumors such as bladder cancer, gastric cancer, gastroesophageal cancer, esophageal cancer, gynecological cancer, breast cancer, rectal adenocarcinoma cancer, colorectal cancer, endometrial cancer, pancreatic cancer and vulvar cancer. The therapeutic candidate is a bivalent bi-specific fusion protein composed of a CD137-specific Anticalin linked to a modified variant of trastuzumab. It is administered intravenously. It is based on Anticalin technology.
Pieris Pharmaceuticals overview
Pieris Pharmaceuticals (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Ra antagonist Anticalin protein. It offers drug candidates such as PRS-060/AZD1402, PRS-220, PRS-440, PRS-342 and PRS-352, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline candidates. Pieris collaborates with AstraZeneca Plc, Boston Pharmaceuticals, Servier SAS, Genentech and Seattle Genetics Inc to develop drug candidates. It operates in the US, Australia and Germany. Pieris is headquartered in Boston, Massachusetts, the US.
For a complete picture of Cinrebafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.